PP
NGM

PDT Partners’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

PDT Partners’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-28,895
Closed -$74.8K – 699
2023
Q2 		$74.8K Sell
28,895
-45,823
-61% -$163K 0.01% 541
2023
Q1 		$305K Sell
74,718
-29,665
-28% -$137K 0.04% 458
2022
Q4 		$524K Buy
104,383
+70,116
+205% +$439K 0.08% 375
2022
Q3 		$448K Buy
+34,267
New +$519K 0.07% 465
2022
Q2 		– Sell
-38,179
Closed -$582K – 1199
2022
Q1 		$582K Sell
38,179
-19,367
-34% -$302K 0.05% 532
2021
Q4 		$1.02M Buy
57,546
+3,300
+6% +$63.3K 0.08% 356
2021
Q3 		$1.14M Buy
54,246
+18,046
+50% +$397K 0.08% 319
2021
Q2 		$714K Buy
+36,200
New +$847K 0.05% 439
2020
Q2 		– Sell
-13,150
Closed -$162K – 855
2020
Q1 		$162K Buy
+13,150
New +$215K 0.01% 582

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PDT Partners's NGM Position: Q3 2023 in Review

PDT Partners sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 28,895 shares — an estimated $74.8K sold.

PDT Partners first reported a position in NGM in Q1 2020 and held it in 9 quarters. The position peaked at $1.14M in Q3 2021. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

  • PDT Partners reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • PDT Partners sold 28,895 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $74.8K.
  • PDT Partners first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 9 quarters.
  • PDT Partners's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.14M in Q3 2021.
  • 94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on PDT Partners's 13F filing for Q3 2023, filed 14 Nov 2023.